EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population

Adriana A M Giuliani iD, Victor Chen, Nancy Law iD

Viruses · 2025

DOI: 10.3390/v18010008 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Adriana A M Giuliani und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Virus Diseases, Transplant Recipients. Die Arbeit nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Transplant patients experience high morbidity and mortality caused by respiratory viral infections (RVIs). In the past decade, numerous methods of prophylaxis and treatment have rapidly developed and continue to expand, with dozens of novel agents in preclinical and clinical trials. This includes recent scientific breakthroughs in virus structure, which have enabled the creation of respiratory syncytial virus (RSV) vaccines. While new vaccines, antivirals, monoclonal antibodies, and non-vaccine agents are becoming more available, their utility and safety in the transplant populations are often uncertain. This review summarizes the current landscape of RVIs in the transplant population, including approaches to pre- and post-exposure prophylaxis and treatment. We discuss the data behind vaccine timing, safety, and efficacy and current pre- and post-transplant recommendations, with a particular focus on influenza, SARS-CoV-2, and RSV. We also examine the potential benefits of antivirals, monoclonal antibodies, and novel agents used as prophylaxis, treatment, or adjuncts. While there remain many knowledge gaps, these new methods and ongoing advancements in RVI treatment and prevention promise to improve transplant patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsVirus DiseasesTransplant RecipientsHumansAntiviral AgentsRespiratory Syncytial Virus InfectionsAntibodies, MonoclonalInfluenza, HumanCOVID-19SARS-CoV-2Post-Exposure Prophylaxis

Stichwörter der Autor:innen

RSVSARS-CoV-2antiviralinfluenzamonoclonal antibodyvaccination

Substanzen

Antiviral AgentsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA.
  • Division of Infectious Diseases, Rady Children's Hospital, San Diego, CA 92123, USA.
  • Department of Pharmacy, University of California San Diego Health, La Jolla, CA 92093, USA.

ORCID-Profile: Adriana A M Giuliani, Nancy Law

Förderung

  • NIAID NIH HHS

Zitieren

APA

Giuliani, A. A. M., Chen, V., & Law, N. (2025). Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population. Viruses. https://doi.org/10.3390/v18010008

Vancouver

Giuliani AAM, Chen V, Law N. Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population. Viruses. 2025. doi:10.3390/v18010008

BibTeX
@article{Giuliani2025,
  author = {Giuliani, Adriana A M and Chen, Victor and Law, Nancy},
  title = {Respiratory Viral Infection Prophylaxis and Treatment in the Transplant Population},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v18010008}
}
Kostenlos starten →